pyridine-3-ylguanidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: pyridine-3-ylguanidine
• 英文别名: 2-pyridin-3-ylguanidine
• 化学式: C₆H₈N₄
• 分子量: 136.156
• InChiKey: UHLKYVNSNIWKGX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  77.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-(pyridin-3-yl)-2,3-di(tert-butoxycarbonyl)guanidine 在 盐酸 作用下， 以 二氯甲烷 为溶剂， 生成 pyridine-3-ylguanidine
  参考文献：
  名称：

  Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 1: 2-Pyridinylguanidines

  摘要：

  The identification of 2-pyridinylguanidines (e.g. 27 and 28) as selective inhibitors of urokinase-type plasminogen activator (uPA) is described. The X-ray crystal structure of 27 has been determined, and modelling has been used to predict binding in the enzyme active site. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00701-6

文献信息

• [EN] METABOTROPIC GLUTAMATE RECEPTOR MODULATORS<br/>[FR] MODULATEURS DES RÉCEPTEURS GLUTAMATERGIQUES MÉTABOTROPES
  申请人：MERZ PHARMA GMBH & CO KGAA

  公开号：WO2012085166A1

  公开（公告）日：2012-06-28

  The invention relates to heterocyclic derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.

  这项发明涉及杂环衍生物及其药用可接受的盐。该发明还涉及一种制备这类化合物的方法。该发明的化合物是mGluR5调节剂，因此对于控制和预防急性和/或慢性神经系统疾病是有用的。
• Compounds and methods for inhibiting mitotic progression
  申请人：Claiborne F. Christopher

  公开号：US20050256102A1

  公开（公告）日：2005-11-17

  This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.

  这项发明涉及用于治疗癌症的化合物和方法。具体而言，该发明提供了抑制枢纽激酶的化合物，包含这些化合物的药物组合物，以及利用这些化合物治疗癌症的方法。
• [EN] COMPOUNDS AND THERAPEUTIC USES THEREOF<br/>[FR] COMPOSÉS ET UTILISATIONS THÉRAPEUTIQUES ASSOCIÉES
  申请人：MYREXIS INC

  公开号：WO2011109441A1

  公开（公告）日：2011-09-09

  The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, ischemia, and other complications associated with these diseases and disorders.

  这项发明涉及化合物、药物组合物和方法，用于治疗癌症、全身性或慢性炎症、类风湿关节炎、糖尿病、肥胖、T细胞介导的自身免疫疾病、缺血以及与这些疾病和疾病相关并发症。
• COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION
  申请人：Claiborne Christopher F.

  公开号：US20090299060A1

  公开（公告）日：2009-12-03

  This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.

  本发明涉及化合物和治疗癌症的方法。具体来说，本发明提供抑制极化激酶的化合物，包含该化合物的制药组合物以及使用该化合物治疗癌症的方法。
• COMPOUNDS AND THERAPEUTIC USES THEREOF
  申请人：Willardsen J. Adam

  公开号：US20120329786A1

  公开（公告）日：2012-12-27

  The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, ischemia, and other complications associated with these diseases and disorders.

  本发明涉及化合物、药物组合物和方法，用于治疗癌症、全身或慢性炎症、类风湿性关节炎、糖尿病、肥胖症、T细胞介导的自身免疫性疾病、缺血以及与这些疾病和疾病相关的其他并发症。